̽����ѡ

I am an assistant professor at the Department of Microbiology, Tumor and Cell Biology at ̽����ѡ. Previously junior group leader (SNSF Ambizione Fellow) with Michael N. Hall's Lab at Biozentrum (University of Basel), Switzerland. Alumnus of the Zubarev Lab at ̽����ѡ and the Gygi Lab at Harvard Medical School.

We have developed unique proteomics tools to study “metabolite-protein” and “host-pathogen” interactions in health and disease. Being a hallmark of cancer, dysregulated cellular metabolism has been/is a viable target for developing anticancer therapeutics. We aim to identify metabolic vulnerabilities in cancer and to develop therapeutic strategies, with a special focus on colon and liver cancers. As a hobby, we also continue developing proteomics techniques to answer questions of bio̽����ѡ importance. 

Read more about our research at SaeiLab.com

Education
2014 - 2019: Ph.D. in Medical Science with Prof. Roman A. Zubarev (supervisor) and Prof. Thomas Helleday (co-supervisor) from Department of Medical Biochemistry and Biophysics, Karolinska Institute. Thesis: Molecular Mechanisms and Targets of New Anticancer Treatments

2015: Research School for Drug Discovery and Development, SciLifeLab, Sweden

2004 - 2010: Doctorate of Pharmacy from Tabriz University of Medical Sciences



Academic Appointments

2024 - present: Assistant Professor at the Department of Microbiology, Cell and Tumor Biology, ̽����ѡ, Stockholm, Sweden

2023 - present: Junior Group Leader (Swiss National Science Foundation Ambizione Fellow) at Biozentrum, University of Basel, Switzerland

2022 - 2023: Postdoctoral fellow at Michael N. Hall's Lab at Biozentrum, University of Basel, Switzerland

2020 - 2022: Postdoctoral fellow at Steven P. Gygi's Lab at Department of Cell Biology, Harvard Medical School, Boston, USA

2019 - 2020: Postdoctoral fellow at Roman A. Zubarev's Lab at Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden



Academic grants, honors and awards

2024: Cancerfonden Project Grant

2024: ̽����ѡ Research Incubator Fellowship

2024: Magnus Bergvalls Stiftelse

2023: Jeanssons Stiftelser

2023: Åke Wibergs Stiftelse

2023: Swedish Research Council Starting Grant within Medicine and Health (6M SEK)

2023: Ambizione Fellowship from Swiss National Science Foundation (11.6M SEK)

2023: Ruth och Richard Julins stiftelse

2023: Alex och Eva Wallströms stiftelse

2022: ̽����ѡ Faculty Funded Assistant Professorship (7M SEK)

2022-2023: ̽����ѡ Research Foundation Grant 

2020-2023: Swedish Research Council International Postdoctoral Fellowship (3, 15M SEK)

2020: Karolinska Institute Research Grant

2020: Loo and Hans Ostermans Foundation Research Grant

2019: Thermo Scientific Tandem Mass Tag Gold Award

2019: CancerFonden Research Grant (co-applicant)

We use novel tools in mass spectrometry-based proteomics, biochemistry, systems biology and data-driven approaches to study cancer metabolism. We are mainly focused on colon cancer at the intersection of cancer cell metabolism, dietary nutrients and the microbiome. The ultimate aim is to develop novel drugs and therapeutic modalities against colon cancer and other metabolic disorders.

Main publications:

15. Ashkarran AA, Gharibi H, Sadeghi SA, Modaresi SM, Wang Q, Lin TJ, Yerima G, Tamadon A, Sayadi M, Jafari M, Lin Z, Ritz D, Khakhniashvili D, Guha A, Mofrad MRK, Sun L, Landry MP, Saei AA*, Mahmoudi AA*. 

Teaching proteomics, tumor biology, cancer metabolism, microbiome-related courses, cell biology and chemistry across four departments at ̽����ѡ